2025
Secondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm
Angarita G, Mayerson T, Pittman B, Natarajan A, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. Secondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm. Journal Of Addiction Medicine 2025 DOI: 10.1097/adm.0000000000001479.Peer-Reviewed Original ResearchCocaine useCocaine self-administration paradigmCocaine Self-AdministrationSelf-administration paradigmTobacco useHeart rateMethylphenidate administrationSelf-AdministrationCocaineDiscriminatory powerAerobic exerciseReceiver Operating CharacteristicMethylphenidateSecondary analysisPrimary outcomeElectrocardiogram tracingsElectrocardiogramExerciseR waveHeartTobaccoOperating characteristics
2024
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J, Lanctôt K. Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2024, 37: 100012. PMID: 40086910, DOI: 10.1016/j.inpsyc.2024.100012.Peer-Reviewed Original ResearchBoston Naming TestMini-Mental State ExamCategory fluencyMild-to-moderate AD patientsClinically significant apathyCognitive change scoresModerate AD patientsHopkins Verbal LearningVerbal learningDigit spanNaming TestVerbal fluencySignificant apathyTrail MakingCognitive changesMeasure apathyMethylphenidateCognitionCognitive scoresState ExamMini-MentalChange scoresApathyAD patientsTrial 2Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J, Lanctôt K. Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Alzheimer's & Dementia 2024, 20: e091793. PMCID: PMC11710533, DOI: 10.1002/alz.091793.Peer-Reviewed Original ResearchMini-Mental State ExamBoston Naming TestDigit Span ForwardCategory fluencyWorsening apathyNPI-aCognitive testsAlzheimer's diseaseCognitive change scoresAssociated with cognitive impairmentBaseline cognitive test scoresCognitive test scoresMild to moderate ADAssociated with performanceNaming TestVerbal fluencyExecutive functionMethylphenidate treatmentMethylphenidate groupTrail MakingCognitive domainsCognitive changesMethylphenidatePlacebo-controlled trialNPI-apathyAdverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
Zeng L, Perin J, Gross A, Shade D, Lanctôt K, Lerner A, Mintzer J, Brawman‐Mintzer O, Padala P, van Dyck C, Porsteinsson A, Craft S, Levey A, Herrmann N, Rosenberg P. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal Of Geriatric Psychiatry 2024, 39: e6108. PMID: 38858522, PMCID: PMC11265565, DOI: 10.1002/gps.6108.Peer-Reviewed Original ResearchConceptsMethylphenidate groupTreating apathyPlacebo-controlled trial of methylphenidateTreatment of apathyAssociated with methylphenidateEffects of methylphenidateTrial of methylphenidateAlzheimer's diseaseFollow-upNo treatment group differencesAdverse effects of methylphenidateDiastolic blood pressureSymptom ChecklistAdverse eventsTreatment group differencesMonitoring weightMethylphenidate useMethylphenidate treatmentMedical comorbiditiesPlacebo groupParticipantsMethylphenidateGroup differencesPlacebo-controlled trialMonthly visits
2023
Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial
Tumati S, Vieira D, Bawa K, Andreazza A, Mintzer J, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Herrmann N, Lanctôt K. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079161.Peer-Reviewed Original ResearchP104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Vieira D, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial. International Psychogeriatrics 2023, 35: 125-126. DOI: 10.1017/s1041610223002557.Peer-Reviewed Original ResearchPotential predictors of treatment outcomePredictors of treatment outcomeResponse to methylphenidateClinically significant apathyAlzheimer's Disease Cooperative Study ActivitiesMedium effect sizeMonths of methylphenidateAlzheimer's diseaseNPI-aMethylphenidate treatmentSignificant apathyApathetic patientsBaseline anxietyAD participantsMethylphenidatePotential predictorsActivities of Daily Living ScaleCompared to placeboNeuropsychiatric symptomsIndex scoreDaily Living ScaleAlzheimer's Disease Cooperative Study Activities of Daily Living ScaleApathyEffect sizeLiving ScaleEffects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
Clark E, Perin J, Herrmann N, Brawman‐Mintzer O, Lanctôt K, Lerner A, Mintzer J, Padala P, Rosenberg P, Sami S, Shade D, van Dyck C, Porsteinsson A, Group F. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12403. PMID: 37538343, PMCID: PMC10394740, DOI: 10.1002/trc2.12403.Peer-Reviewed Original ResearchNeuropsychiatric symptomsEffects of methylphenidateAlzheimer's diseaseSecondary analysisNeuropsychiatric Inventory scoresElation/euphoriaSymptoms of apathyIndividual neuropsychiatric symptomsPresentation of symptomsImpact of methylphenidateIndividual domain scoresAppetite/Catecholaminergic dysfunctionMonth 6Neuropsychiatric InventoryCaregiver scoresNPI domainsNew symptomsTreatment periodDomain scoresMeaningful improvementsMethylphenidateSymptomsPlaceboDiseaseHeterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg P, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Padala K, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. American Journal Of Geriatric Psychiatry 2023, 31: 1077-1087. PMID: 37385898, PMCID: PMC10765607, DOI: 10.1016/j.jagp.2023.06.002.Peer-Reviewed Original ResearchConceptsDiastolic blood pressureBlood pressureClinical predictorsDisease patientsAlzheimer's Disease Cooperative Study-ActivitiesHg diastolic blood pressureOptimal diastolic blood pressureMulti-center clinical trialDaily Living ScaleYears of ageAlzheimer's disease patientsHeterogeneity of responseApathy domainApathetic patientsClinical trialsFunctional impairmentTreatment benefitSignificant apathyLiving ScaleImpaired functionBaseline anxietyCholinesterase inhibitorsMedium effect sizeMethylphenidatePotential predictorsCost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.Peer-Reviewed Original ResearchConceptsCost-consequence analysisTreatment of apathyFive-level questionnaireTrial 2Quality of lifeBinary logistic regressionPlacebo groupPlacebo treatmentMethylphenidate treatmentSignificant apathyHealth utilityResource utilization costsAlzheimer's diseaseLogistic regressionMethylphenidateTime interactionLevel questionnaireHealthcare systemCost predictorsMeasures analysisPatientsTreatmentDiseaseMonthsUtilization costsCost Consequence Analysis of ADMET 2
Mah E, Lanctôt K, Chen Q, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Mintzer J, Herrmann N. Cost Consequence Analysis of ADMET 2. American Journal Of Geriatric Psychiatry 2023, 31: s101. DOI: 10.1016/j.jagp.2022.12.147.Peer-Reviewed Original ResearchCost-consequence analysisHealth utilityPlacebo groupMethylphenidate treatmentEuroQol-five dimensions-five levelsAlzheimer's diseaseHealth statesCommon neuropsychiatric symptomsHealth utility scoresQuality of lifeBinary logistic regressionApathy treatmentBaseline demographicsDifferent time pointsPreference-based measuresMethylphenidate groupNeuropsychiatric symptomsClinical trialsEQ-5DSignificant apathyPatientsUtility scoresBetter health stateLogistic regressionMethylphenidateCorrelation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial
Lanctôt K, Sankhe K, Perin J, Herrmann N, Brawman-Mintzer O, Lerner A, Mintzer J, Padala P, Rosenberg P, Shade D, van Dyck C, Porsteinsson A. Correlation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial. American Journal Of Geriatric Psychiatry 2023, 31: s100-s101. DOI: 10.1016/j.jagp.2022.12.146.Peer-Reviewed Original ResearchDigit Span BackwardMini-Mental Status ExaminationSelective attentionGlobal cognitionApathy scoresGreater cognitive declineExecutive functionDigit spanCognitive testsCognitionMethylphenidate groupApathy symptomsCognitive declineSignificant apathyMethylphenidateCognitive impairmentStatus ExaminationApathy subscaleMemoryChange scoresApathyDisease dementiaAlzheimer's disease dementiaParticipantsAttention
2022
Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers
Zakiniaeiz Y, Hoye J, Ryan Petrulli J, LeVasseur B, Stanley G, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Chen MK, Matuskey D, Barron DS, Kelmendi B, Fulbright RK, Hampson M, Cosgrove KP, Morris ED. Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers. Brain Behavior And Immunity 2022, 106: 262-269. PMID: 36058419, PMCID: PMC10097458, DOI: 10.1016/j.bbi.2022.08.016.Peer-Reviewed Original ResearchConceptsEffects of LPSDopamine elevationTobacco smokersHealthy controlsSystemic inflammationDopamine systemImmune-brain interactionReward-related brain regionsAdministration of placeboAdministration of LPSSmoking statusRepeated-measures ANOVAPathophysiology of addictionDrug dosingPlaceboIndependent cohortSmokersDrug reinforcementEffect size determinationImmune systemRandomized orderBrain regionsLPSMethylphenidatePBO condition
2021
Apathy in Dementia Methylphenidate Trial 2 (ADMET2): Results of a phase III, placebo‐controlled, double‐blind, 6‐month, multi‐center, randomized clinical trial
Mintzer J, Scherer R, Drye L, Lanctôt K, Rosenberg P, Herrmann N, Padala P, Brawman‐Mintzer O, Lerner A, Levey A, Porsteinsson A, van Dyck C. Apathy in Dementia Methylphenidate Trial 2 (ADMET2): Results of a phase III, placebo‐controlled, double‐blind, 6‐month, multi‐center, randomized clinical trial. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.051489.Peer-Reviewed Original ResearchAlzheimer's diseasePlacebo groupMethylphenidate groupClinical trialsAD Cooperative Study-Clinical Global ImpressionPhase IIITreatment of apathyClinical Global ImpressionRatings of improvementADCS-CGICAdverse eventsSecondary outcomesMonth 6Primary outcomeNeuropsychiatric symptomsSafety profileGlobal ImpressionSmall studyViable treatmentStudy participantsMean differenceMonthsMethylphenidatePrevious trialsTrials
2020
Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy – a commentary on Rodrigues et al. (2020)
Farhat LC, Bloch MH. Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy – a commentary on Rodrigues et al. (2020). Journal Of Child Psychology And Psychiatry 2020, 62: 701-703. PMID: 33368287, DOI: 10.1111/jcpp.13374.Peer-Reviewed Original ResearchConceptsContext of autism spectrum disorderAttention-deficit hyperactivity disorder symptomsHyperactivity disorder symptomsAutism spectrum disorderContext of autismEvidence baseDisorder symptomsIntellectual disabilityTic disordersADHD pharmacotherapySpectrum disorderADHDDisordersIndividual predictionsMeta-analysesEvidence of treatmentPredictive of responseAripiprazoleRisperidoneAtomoxetineMethylphenidatePotential avenuesGuanfacineAutismPharmacotherapyThe rate of dasotraline brain entry is slow following intravenous administration
Lew R, Constantinescu CC, Holden D, Carson RE, Carroll V, Galluppi G, Koblan KS, Hopkins SC. The rate of dasotraline brain entry is slow following intravenous administration. Psychopharmacology 2020, 237: 3435-3446. PMID: 32813030, PMCID: PMC7651685, DOI: 10.1007/s00213-020-05623-8.Peer-Reviewed Original ResearchConceptsSynaptic dopamine levelsDopamine levelsDAT occupancyPositron emission tomographyIntravenous administrationSynaptic dopamineRhesus monkeysSlow oral absorptionNorepinephrine reuptake inhibitorsBlood-brain barrierHalf-maximal displacementDopamine transporter inhibitionRecreational drug abusersBrain entryResultsIntravenous administrationReuptake inhibitorsPharmacodynamic effectsD2 receptorsRaclopride bindingAssociated elevationDasotralineDrug abusersMethylphenidateTransporter inhibitionEmission tomographyNeurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate
van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. American Journal Of Geriatric Psychiatry 2020, 29: 51-62. PMID: 32461027, PMCID: PMC7641967, DOI: 10.1016/j.jagp.2020.04.026.Peer-Reviewed Original ResearchConceptsTreatment of apathyAlzheimer's diseaseCortical-basal ganglia circuitsPrefrontal cortexMotivated behaviorPublic health burdenSymptoms of apathyCatecholaminergic treatmentNeurobiologic rationaleNeuropsychiatric symptomsDopamine actionGanglia circuitsHealth burdenThalamocortical circuitsCognitive symptomsMethylphenidate actionsCatecholamine actionNeuronal circuitsSymptomsDiseaseApathetic behaviorTreatmentInitial trialMethylphenidateAD resultsEffects of sub-chronic methylphenidate on risk-taking and sociability in zebrafish (Danio rerio)
Brenner R, Oliveri A, Sinnott-Armstrong W, Levin E. Effects of sub-chronic methylphenidate on risk-taking and sociability in zebrafish (Danio rerio). Naunyn-Schmiedeberg's Archives Of Pharmacology 2020, 393: 1373-1381. PMID: 32025747, PMCID: PMC7716188, DOI: 10.1007/s00210-020-01835-z.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderSub-chronic dosesTreated with stimulant medicationVisual stimuliDecreased locomotor responseEffects of methylphenidateDeficit hyperactivity disorderRisk-takingImpaired avoidanceLocomotor responseAvoidance paradigmMethylphenidate exposureSocial stimuliStimulant medicationPsychiatric disordersHyperactivity disorderBehavioral functionsMethylphenidateNovel tankNeurobehavioral impairmentsDosing paradigmNeurobehavioral toxicityDecreased activity levelsAdult zebrafishStimuli
2017
Methylphenidate enhances implicit learning in healthy adults
Klinge C, Shuttleworth C, Muglia P, Nobre A, Harmer C, Murphy S. Methylphenidate enhances implicit learning in healthy adults. Journal Of Psychopharmacology 2017, 32: 70-80. PMID: 28946787, DOI: 10.1177/0269881117731472.Peer-Reviewed Original ResearchConceptsMeasures of cognitionImplicit cognition measuresEffects of methylphenidateCognitive measuresImplicit learningImplicit measures of cognitionDose of methylphenidateTask-switching taskCognition-enhancing effectsSensitivity to pharmacological interventionExperimental medicine studiesPharmacological interventionsPriming taskImplicit cognitionDevelopment of pharmacological interventionsImplicit measuresCognitive effectsExplicit measuresEnhance cognitionMethylphenidateHealthy volunteersCognitionAbsence of biomarkersImprove learningMale volunteers
2016
Efficacy of Stimulants for Psychiatric Symptoms in Individuals with Traumatic Brain Injury
Maksimowski MB, Tampi RR. Efficacy of Stimulants for Psychiatric Symptoms in Individuals with Traumatic Brain Injury. Annals Of Clinical Psychiatry 2016, 28: 156-166. PMID: 27490831, DOI: 10.1177/104012371602800303.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryEfficacy of stimulantsPsychiatric symptomsBrain injuryMajority of studiesSelf-reported side effectsDiagnosis of TBIMean arterial pressureSignificant differencesFirst-time administrationSignificant improvementUse of stimulantsPlacebo groupArterial pressureSignificant treatment effectDisability ratingsInclusion criteriaStimulant groupDepressive symptomsTreatment groupsSide effectsStimulant administrationHuman patientsSystematic reviewMethylphenidateThe Effects of Methylphenidate on Resting-State Functional Connectivity of the Basal Nucleus of Meynert, Locus Coeruleus, and Ventral Tegmental Area in Healthy Adults
Kline RL, Zhang S, Farr OM, Hu S, Zaborszky L, Samanez-Larkin GR, Li CS. The Effects of Methylphenidate on Resting-State Functional Connectivity of the Basal Nucleus of Meynert, Locus Coeruleus, and Ventral Tegmental Area in Healthy Adults. Frontiers In Human Neuroscience 2016, 10: 149. PMID: 27148006, PMCID: PMC4834346, DOI: 10.3389/fnhum.2016.00149.Peer-Reviewed Original ResearchResting-state functional connectivityEffects of methylphenidateAttention deficit hyperactivity disorderLocus coeruleusPositive connectivityNegative connectivityFunctional connectivityBrain resting-state functional connectivityHealthy adultsDeficit hyperactivity disorderBasal nucleusDose of methylphenidateMiddle occipital gyrusSeed regionVTA/SNcVentral tegmental area/substantia nigraCognitive controlVentral tegmental areaHyperactivity disorderOccipital gyrusT-testCatecholaminergic signalingTwo-sample t-testMethylphenidatePrecentral gyrus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply